A Radical Proposal to Preserve Cell and Gene Therapy Innovation
Cell and gene therapies are amazing medical breakthroughs but if we don’t find ways to pay for them, the development pipeline will fail.
Cell and gene therapies are amazing medical breakthroughs but if we don’t find ways to pay for them, the development pipeline will fail.
The healthcare affordability crisis in the U.S. has become a trust crisis, with a growing share of Americans walking away from care altogether. Industry leaders say the fix requires something the system has never really done: starting with the patient.
CMS Administrator Dr. Mehmet Oz outlined the agency's strategy for making healthcare more affordable during a Tuesday address at the HFMA Annual Conference, touching on everything from Medicare fraud to drug pricing to nutrition.
Healthcare affordability czar Casey Mulligan laid out the economic philosophy guiding the Trump administration's approach to healthcare costs during a recent conference address. He argued that provider taxes and state-directed payments inflate healthcare spending far beyond Medicaid and ultimately raise costs for employers and taxpayers.
Last week, Trump proposed cutting out insurers and giving Americans cash to buy their own healthcare, claiming it would lower costs. Ali Diab, an economist and CEO of Collective Health, said the plan overlooks the real problem: concentrated payer power, opaque pricing and the financial risk people face without insurance.
At a time when 98 million prescriptions are abandoned due to cost surprises, it’s critical that all four categories of prescription drug prices are available so consumers can determine how to obtain needed medications at the lowest cost.
Enterprise EHR boosts scalability, interoperability, and governance for large healthcare systems.
Rising healthcare costs and flaws in the Medicare Advantage program are likely to dominate healthcare reform discussions in 2026, according to one PitchBook analyst. Potential policy changes could focus on improving affordability in the ACA market and fixing distorted incentives in Medicare Advantage.
The leaders who will thrive are those who can see both sides of every equation: mission and margin, empathy and efficiency, innovation and trust. They’re the ones building organizations that don’t just survive policy shifts and economic pressure, but use them as catalysts for progress.
The Trump administration can immediately take these two price transparency administrative actions to reduce costs and improve affordability.
Every day, patients are making agonizing choices to skip medications due to cost, and the fallout is evident in worsening health and avoidable hospitalizations. Health systems are in a prime position to break this cycle by acting as advocates for their patients’ financial as well as physical well-being.
To make healthcare more affordable in the short term and the long run, time-to-pay must become an essential component of every health plan with any out-of-pocket responsibility.
It's a bold attempt to recalibrate global drug pricing — with U.S. patients at the center. But without clear enforcement, legal grounding, or international cooperation, its future remains very uncertain.